Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ardelyx, Inc. (ARDX : NSDQ)
 
 • Company Description   
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

Number of Employees: 395

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.70 Daily Weekly Monthly
20 Day Moving Average: 4,029,930 shares
Shares Outstanding: 239.26 (millions)
Market Capitalization: $1,124.50 (millions)
Beta: 0.60
52 Week High: $7.18
52 Week Low: $3.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 26.34% 21.61%
12 Week -2.39% -17.90%
Year To Date -7.30% -13.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 Fifth Avenue Suite 210
-
Waltham,MA 02451
USA		 ph: 510-745-1700
fax: 510-745-0493		 investor@ardelyx.com http://www.ardelyx.com
 
 • General Corporate Information   
Officers
Michael Raab - President and Chief Executive Officer
David Mott - Chairman
Justin Renz - Chief Financial and Operations Officer
Robert Bazemore - Director
Richard Rodgers - Director

Peer Information
Ardelyx, Inc. (GSAC)
Ardelyx, Inc. (CASI)
Ardelyx, Inc. (ALCD.)
Ardelyx, Inc. (OMNN)
Ardelyx, Inc. (CGPI.)
Ardelyx, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 039697107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 239.26
Most Recent Split Date: (:1)
Beta: 0.60
Market Capitalization: $1,124.50 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.40 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.72
Price/Cash Flow: -
Price / Sales: 3.11
EPS Growth
vs. Year Ago Period: -54.55%
vs. Previous Quarter: -950.00%
Sales Growth
vs. Year Ago Period: 61.04%
vs. Previous Quarter: -36.18%
ROE
06/30/25 - -
03/31/25 - -34.45
12/31/24 - -24.87
ROA
06/30/25 - -
03/31/25 - -13.81
12/31/24 - -10.51
Current Ratio
06/30/25 - -
03/31/25 - 4.12
12/31/24 - 4.58
Quick Ratio
06/30/25 - -
03/31/25 - 3.81
12/31/24 - 4.31
Operating Margin
06/30/25 - -
03/31/25 - -14.86
12/31/24 - -11.73
Net Margin
06/30/25 - -
03/31/25 - -14.86
12/31/24 - -11.73
Pre-Tax Margin
06/30/25 - -
03/31/25 - -14.59
12/31/24 - -11.65
Book Value
06/30/25 - -
03/31/25 - 0.61
12/31/24 - 0.73
Inventory Turnover
06/30/25 - -
03/31/25 - 3.18
12/31/24 - 3.60
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.04
12/31/24 - 0.87
Debt-to-Capital
06/30/25 - -
03/31/25 - 50.95
12/31/24 - 46.54
 

Powered by Zacks Investment Research ©